Ovid Therapeutics Inc

A Delaware federal judge dismissed Acuitas Therapeutics' attempt to clear Pfizer's Comirnaty vaccine from GSK patent claims, leaving the patent dispute unresolved. Pfizer shares fell 1.42% to $25.68.

Moderna's Q1 revenue surged to $389M on international Covid vaccine sales, but a $900M patent charge pushed net loss to $1.34B. Shares fell 2.7%.

Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.

Bitcoin fell back Sunday as geopolitical tensions resurfaced, though continued institutional demand via spot ETFs helped cushion the decline. Morgan Stanley's new Bitcoin fund marked a milestone for Wall Street adoption.

Pfizer shares declined 1% to $26.60 Friday after GSK secured expanded FDA approval for its RSV vaccine, challenging Pfizer's market position. Encouraging clinical results for blood thinner Eliquis helped cushion the drop.

Apple shares declined nearly 2% to $255.76, trimming its market cap to approximately $4.05 trillion. The drop coincided with a broader tech sell-off driven by oil price spikes and the launch of new, more affordable Apple devices.

Bitcoin declined over 1% as escalating Middle East tensions drove oil prices higher, stoking inflation concerns. However, U.S. spot Bitcoin ETFs recorded significant inflows, highlighting conflicting market forces.

Nvidia shares declined 0.7% to $186.69 in Thursday trading, giving back some of Wednesday's gains. The pullback comes ahead of next week's quarterly earnings report and amid broader semiconductor sector weakness.